Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3105-3114

  Laxton, Carl ^a   Brady, Kevin ^a   Moschos, Sterghios ^a   Turnpenny, Paul ^a   Rawal, Jaiessh ^a   Pryde, David C ^a   Sidders, Ben ^a   Corbau, Romu ^a   Pickford, Chris ^a   Murray, E J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; LOCKED NUCLEIC ACID; OLIGOMER; RIBONUCLEASE H;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CODON; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; GENOME ANALYSIS; HEPATITIS C VIRUS; INTERNAL RIBOSOME ENTRY SITE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN TARGETING; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; HEPACIVIRUS; HUMANS; KIDNEY; LIVER; MICE; OLIGONUCLEOTIDES, ANTISENSE; RIBOSOMES;

EID: 79959223747     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00222-11     Document Type: Article

References (42)

1. Alt, M., et al. 1999. Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation. Eur. J. Clin. Invest. 29:868-876.
2. Alt, M., R. Renz, P. H. Hofschneider, G. Paumgartner, and W. H. Caselmann. 1995. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 22:707-717.
3. Bennett, C. F., and E. E. Swayze. 2010. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50:259-293.
4. Blight, K. J., J. A. McKeating, J. Marcotrigiano, and C. M. Rice. 2003. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77:3181-3190.
5. Braasch, D. A., Y. Liu, and D. R. Corey. 2002. Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res. 30:5160-5167.
6. Chary, A., and M. Holodniy. 2010. Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. Rev. Recent Clin. Trials 5:158-173.
7. Cooper, C. 2010. Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success. Can. J. Gastroenterol. 24:385-390.
8. Crooke, S. T. (ed.) 2007. Antisense drug technology: principles, strategies and applications, p. 537-558. CRC Press, Boca Raton, FL.
9. Dahari, H., R. M. Ribeiro, C. M. Rice, and A. S. Perelson. 2007. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J. Virol. 81:750-760.
10. Detzer, A., M. Overhoff, A. Mescalchin, M. Rompf, and G. Sczakiel. 2008. Phosphorothioate-stimulated cellular uptake of siRNA: a cell culture model for mechanistic studies. Curr. Pharm. Des. 14:3666-3673.
11. Diaz-Toledano, R., A. Ariza-Mateos, A. Birk, B. Martinez-Garcia, and J. Gomez. 2009. In vitro characterization of a miR-122-sensitive double-helical switch element in the 5′ region of hepatitis C virus RNA. Nucleic Acids Res. 37:5498-5510.
12. Elmen, J., et al. 2008. LNA-mediated microRNA silencing in non-human primates. Nature 452:896-899. (Pubitemid 351550859)
13. Frese, M., et al. 2003. Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J. Gen. Virol. 84:1253-1259.
14. Gordon, S. C., et al. 2003. Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor, given for 12 weeks. Hepatology 38:306A.
15. Grunweller, A., and R. K. Hartmann. 2007. Locked nucleic acid oligonucleotides: the next generation of antisense agents? BioDrugs 21:235-243.
16. Hanecak, R., et al. 1996. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J. Virol. 70:5203-5212. (Pubitemid 26240692)
17. Henke, J. I., et al. 2008. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 27:3300-3310.
18. Jangra, R. K., M. Yi, and S. M. Lemon. 2010. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J. Virol. 84:6615-6625.
19. Jopling, C. L., M. Yi, A. M. Lancaster, S. M. Lemon, and P. Sarnow. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309:1577-1581. (Pubitemid 41266486)
20. Kapadia, S. B., and F. V. Chisari. 2005. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl. Acad. Sci. U. S. A. 102:2561-2566.
21. Kato, T., et al. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. (Pubitemid 37500445)
22. Kaur, H., B. R. Babu, and S. Maiti. 2007. Perspectives on chemistry and therapeutic applications of locked nucleic acid (LNA). Chem. Rev. 107:4672-4697. (Pubitemid 350225863)
23. Krutzfeldt, J., et al. 2005. Silencing of microRNAs in vivo with 'antagomirs.' Nature 438:685-689.
24. Kurreck, J., E. Wyszko, C. Gillen, and V. A. Erdmann. 2002. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30:1911-1918.
25. Lanford, R. E., et al. 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201.
26. Lewis, A. P., and C. L. Jopling. 2010. Regulation and biological function of the liver-specific miR-122. Biochem. Soc Trans. 38:1553-1557.
27. Lima, W. F., V. Brown-Driver, M. Fox, R. Hanecak, and T. W. Bruice. 1997. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. Biol. Chem. 272:626-638.
28. McHutchison, J. G., et al. 2006. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J. Hepatol. 44:88-96. (Pubitemid 41772521)
29. Norman, K. L., and P. Sarnow. 2010. Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J. Virol. 84:666-670.
30. Randall, G., A. Grakoui, and C. M. Rice. 2003. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad. Sci. U. S. A. 100:235-240.
31. Romero-Lopez, C., and A. Berzal-Herranz. 2009. A long-range RNA-RNA interaction between the 5′ and 3′ ends of the HCV genome. RNA 15:1740-1752.
32. Sarasin-Filipowicz, M., J. Krol, I. Markiewicz, M. H. Heim, and W. Filipowicz. 2009. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 15:31-33.
33. Soler, M., J. G. McHutchison, T. J. Kwoh, F. A. Dorr, and J. M. Pawlotsky. 2004. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir. Ther. 9:953-968.
34. Stiffler, J. D., et al. 2009. Focal distribution of hepatitis C virus RNA in infected livers. PLoS One 4:e6661.
35. Swayze, E. E., et al. 2007. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35:687-700. (Pubitemid 46232083)
36. Tsukiyama-Kohara, K., N. Iizuka, M. Kohara, and A. Nomoto. 1992. Internal ribosome entry site within hepatitis C virus RNA. J. Virol. 66:1476-1483.
37. Veedu, R. N., and J. Wengel. 2009. Locked nucleic acid as a novel class of therapeutic agents. RNA Biol. 6:321-323.
38. Villanueva, R. A., et al. 2010. miR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes. Antiviral Res. 88:119-123.
39. Vona, G., et al. 2004. Intrahepatic hepatitis C virus RNA quantification in microdissected hepatocytes. J. Hepatol. 40:682-688. (Pubitemid 38367792)
40. Wahlestedt, C., et al. 2000. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. U. S. A. 97:5633-5638.
41. Wakita, T., and J. R. Wands. 1994. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J. Biol. Chem. 269:14205-14210.
42. Ye, J. 2007. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog. 3:e108.